Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial - Quiz - MDSpire

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial

  • By

  • Melinda Gooderham

  • Christopher G. Bunick

  • JiaDe Yu

  • Douglas Maslin

  • Shannon K. R. Schneider

  • Marie Louise Østerdal

  • Anders Søhoel

  • Daniel Elenius Madsen

  • Lawrence F. Eichenfield

  • May 17, 2026

Share

Original Source(s)

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial

  • by Melinda Gooderham, Christopher G. Bunick, JiaDe Yu, Douglas Maslin, Shannon K. R. Schneider, Marie Louise Østerdal, Anders Søhoel, Daniel Elenius Madsen, Lawrence F. Eichenfield

  • May 17, 2026

Related Content

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.